These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1492856)

  • 1. Dihydroergocristine. Recent research and development.
    Mailland F
    Arzneimittelforschung; 1992 Nov; 42(11A):1379-80. PubMed ID: 1492856
    [No Abstract]   [Full Text] [Related]  

  • 2. [Dihydroergocristine. Recent research and development].
    Arzneimittelforschung; 1992 Nov; 42(11A):1379-421. PubMed ID: 1492855
    [No Abstract]   [Full Text] [Related]  

  • 3. [Blood prolactin-lowering activity of dihydroergocristine].
    Cocchi D; Müller EE; Boselli P; Faini D
    Farmaco Sci; 1985 Jul; 40(7):534-40. PubMed ID: 3930286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dihydroergocristine. A review of pharmacology and toxicology].
    Coppi G
    Arzneimittelforschung; 1992 Nov; 42(11A):1381-90. PubMed ID: 1492857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Action of dihydroergocristine on enzyme activities related to energy transduction.
    Gorini A; Villa RF
    Farmaco Prat; 1983 May; 38(5):191-9. PubMed ID: 6409665
    [No Abstract]   [Full Text] [Related]  

  • 6. [Alpha-blocking activity of raubasine-dihydroergocristine combination in the demedullated rat].
    Roquebert J; Gomond P; Demichel P
    Ann Pharm Fr; 1983; 41(1):69-75. PubMed ID: 6137989
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of topical dihydroergocristine on intraocular pressure, aqueous humor dynamics and pupil diameter in conscious rabbits. A comparative study with timolol and pilocarpine.
    Santafé Oroz J; Segarra Domenech J; Garrido García M; Pablo Martínez V
    Methods Find Exp Clin Pharmacol; 1991 May; 13(4):231-8. PubMed ID: 1908543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Action of dihydroergocristine at pre- and postsynaptic alpha-adrenoceptors in the rat isolated vas deferens].
    Roquebert J; Demichel P; Gomond P; Malek A
    J Pharmacol; 1983; 14(2):151-9. PubMed ID: 6134866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of sulpiride-induced prolactin secretion by dihydroergocristine in man.
    Poli M; Caviezel F; Girardi AM; Bosi E; Pozza G
    Adv Biochem Psychopharmacol; 1980; 24():445-9. PubMed ID: 6773304
    [No Abstract]   [Full Text] [Related]  

  • 10. Actions and interactions of ergotamine and dihydroergocristine in rat aortic strips.
    Grana E; D'Agostino G; Zonta F; Lucchelli A
    Farmaco Sci; 1981 May; 36(5):334-43. PubMed ID: 6786918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Trials in the treatment of cerebrovascular insufficiency with the monodrug dihydroergocristine. A multicentric study].
    Finke J; Haehn KD; Haase W
    Med Welt; 1982 Jul; 33(28):1042-7. PubMed ID: 6811832
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical trials with dihydroergocristine in patients with vascular and cerebral insufficiency].
    Ingelmo M; Vivancos J; Peri J; Balcells Gorina A
    Rev Clin Esp; 1980 Dec; 159(6):399-402. PubMed ID: 6784197
    [No Abstract]   [Full Text] [Related]  

  • 13. The effects of Hydergine on neurotransmitters.
    Ermini M
    Br J Clin Pract Suppl; 1985 Jun; 39():11-5. PubMed ID: 2864053
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical and therapeutic experience in 151 consecutive protocolized cases with vertigo syndrome of cervical origin. Comparative study of a cinnarizine and dihydroergocristine combination with a cinnarizine and dihydroergocristine plus anti-inflammatory agents combination].
    Bartual J; Vidal J; Magro E; Roquette J
    Acta Otorrinolaringol Esp; 1988; 39(5):331-8. PubMed ID: 3152492
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapeutic effectiveness and safety of dihydroergocristine. A study of 9,702 patients].
    Mailland F; Zottino G
    Fortschr Med; 1986 Mar; 104(11):239-42. PubMed ID: 3084366
    [No Abstract]   [Full Text] [Related]  

  • 16. Measuring the inhibition of TRH-stimulated prolactin by dihydroergocristine (DEC) in man: an indirect assessment of bioavailability.
    Venitz J; Lücker PW; Albrecht H; Mailland F
    Methods Find Exp Clin Pharmacol; 1984 Oct; 6(10):645-7. PubMed ID: 6439963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Controlled clinical trial of dihydroergocristine in neuropsychiatric disorders in cerebrovascular insufficiency].
    Muchnik S
    Boll Chim Farm; 1982 May; 121(5):33S-46S. PubMed ID: 6814466
    [No Abstract]   [Full Text] [Related]  

  • 18. [Quantitative rheographic study of the effects of a new drug combination: raubasine/dihydroergocristine].
    Henriet M; Jacquy J; Noel G
    Brux Med; 1974 Dec; 54(12):743-5. PubMed ID: 4215548
    [No Abstract]   [Full Text] [Related]  

  • 19. [Evaluation of the therapeutic effectiveness of a piracetam plus dihydroergocristine combination in the treatment of vertigo].
    López Martínez R
    Acta Otorrinolaringol Esp; 1988; 39(4):287-8. PubMed ID: 3152560
    [No Abstract]   [Full Text] [Related]  

  • 20. Animal model of anxiety: the effect of chronic dihydroergotoxine treatment in the genetically hypertensive rats of Koletsky type and in the rats of Wistar strain.
    Golda V; Petr R
    Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1990; 33(2):177-89. PubMed ID: 2098906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.